Ibio Inc
Change company Symbol lookup
Select an option...
IBIO Ibio Inc
JPS Nuveen Preferred & Income Securities Fund
EFSC Enterprise Financial Services Corp
CYPS Cyclo3pss Corp
CXW CoreCivic Inc
STM STMicroelectronics NV
NYT New York Times Co
SOS Sos Ltd
DDOC DERMADOCTOR, INC.
CLOV Clover Health Investments Corp
Go

Health Care : Biotechnology | Small Cap Value
Company profile

iBio, Inc. is a developer of next-generation biopharmaceuticals using its proprietary artificial intelligence (AI)-Driven Discovery Platform and FastPharming Manufacturing System. The Company is focusing its technologies on the research and development of novel products at its Drug Discovery Center in California. The Company through its FastPharming Manufacturing System and GlycaneeringSM Technologies develop its portfolio of proprietary biologic drug candidates. The Company operates through two segments: Biopharmaceuticals, and Bioprocessing. Its Biopharmaceuticals segment is engaged in large molecule discovery, development, and licensing activities. Its Bioprocessing segment is engaged in contract development and manufacturing services for recombinant proteins. Its pipeline includes IBIO-100, IBIO-101, IBIO-202, and IBIO-400. Its subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services along with GlycaneeringSM Development Services.

Closing Price
$1.70
Day's Change
0.10 (6.25%)
Bid
--
Ask
--
B/A Size
--
Day's High
1.76
Day's Low
1.53
Volume
(Heavy Day)
Volume:
96,296

10-day average volume:
50,426
96,296

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Kiromic BioPharma (KRBP) Investors with Losses to Lead Plaintiff Deadline in Securities Class Action

12:59 pm ET October 4, 2022 (Newsfile) Print

San Francisco, California--(Newsfile Corp. - October 4, 2022) - Hagens Berman urges Kiromic BioPharma, Inc. (NASDAQ: KRBP) investors who purchased Kiromic shares to submit your losses now.

Relevant Period: June 25, 2021 - Feb. 2, 2022

Lead Plaintiff Deadline: Oct. 4, 2022

Visit:https://www.hbsslaw.com/investor-fraud/KRBP

Contact An Attorney Now:KRBP@hbsslaw.com

844-916-0895

Kiromic BioPharma, Inc. (KRBP) Securities Class Action:

Hagens Berman Sobol Shapiro LLP announces that it has filed a class action lawsuit against Kiromic BioPharma, Inc. ("Kiromic" or the "Company") (NASDAQ: KRBP) and against certain officers and directors of the Company as well as other parties. The class action, filed in the United States District Court for the Southern District of New York, titled Podmore v. Kiromic BioPharma, Inc., et al., Case No. 1:22-cv-08433, is brought on behalf of a class consisting of all persons and entities that purchased or otherwise acquired: (1) Kiromic common stock pursuant and/or traceable to the Offering Documents (defined below) and/or (2) Kiromic securities between June 25, 2021 and February 2, 2022, both dates inclusive (the "Class Period"). Plaintiff pursues claims against Defendants under the Securities Act of 1933 and the Securities Exchange Act of 1934.

If you are a shareholder who purchased Kiromic shares during the class period, you have until Oct. 4, 2022, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained here. Click here to discuss your legal rights with Hagens Berman.

The Company's public offering closed on July 2, 2021 (the "Offering") and was conducted pursuant to a registration statement filed with the SEC on June 25, 2021 ("Registration Statement") and a final prospectus dated June 29, 2021 (the "Prospectus," with the Registration Statement, the "Offering Documents").

The Complaint challenges Defendants' disclosures about its development of two cancer treatment product candidates, ALEXIS-PRO-1 and ALEXIS-ISO-1.

The Complaint alleges that in the Offering Documents and during the Class Period, Defendants failed to disclose that the FDA had, prior to the filing of the Registration Statement and Prospectus, imposed a clinical hold, and in fact, contained statements indicating that it had not. Given that the Offering closed on July 2, 2021, more than thirty (30) days after the Company submitted the IND applications for its two immunotherapy product candidates, investors were assured that no clinical hold had been issued and clinical trials would commence.

But on July 16, 2021, Kiromic disclosed that it had received "comments" from the FDA on its two INDs.

Then, on Aug. 13, 2021, the Company clarified that the FDA had actually put the INDs on "clinical hold."

Finally, on Feb. 2, 2022, Kiromic essentially admitted that it had not been forthcoming with investors concerning the status of the INDs. Specifically, the Company revealed that it commenced an internal investigation based on complaints lodged by its former CFO, who abruptly departed in October 2021.

The internal investigation uncovered that the FDA had first informed the Company of the clinical hold on June 16 and June 17, 2021 - material facts not disclosed in Kiromic's July 2021 public offering documents. Kiromic admitted that this material omission could subject the Company to liability under the securities laws.

These events have driven the price of Kiromic shares sharply lower, injuring investors.

Investors who purchased or otherwise acquired shares of Kiromic should contact the Firm prior to the October 4, 2022 lead plaintiff motion deadline. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you invested in Kiromic and have significant losses, or have knowledge that may assist the firm's investigation, click here to discuss your legal rights with Hagens Berman.

Whistleblowers: Persons with non-public information regarding Kiromic should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email KRBP@hbsslaw.com.

# # #

About Hagens Berman

Hagens Berman is a global plaintiffs' rights complex litigation law firm focusing on corporate accountability through class-action law. The firm is home to a robust securities litigation practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and fraud. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.

Contact:

Reed Kathrein, 844-916-0895

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/139476

comtex tracking

COMTEX_415911514/2523/2022-10-04T12:59:25

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.